Induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs), or cultured heart muscle cells, offer many opportunities to advance basic science, pharmaceutical screening, and personalized medicine for improved efficacy and safety in determining individual drug regimens. However, iPSC-CMs are functionally immature in all aspects of physiology including morphology, contractility, electrophysiology, calcium handling, and metabolism. For this reason, they are not able to recapitulate a useful physiological profile for preclinical or clinical levels of use.

MetabolIQ has developed patent-pending technology to enhance the physiological maturation of iPSC-CMs. Proof of concept has been demonstrated in both purified monolayer and organoid culture systems, with systematic physiological and multi-omic validation.

While enabling worldwide distribution of this iPSC-CM solution, MetabolIQ is simultaneously leveraging the technology to develop high-throughput safety screens for preclinical pharmaceutical testing, as well as cell therapy applications.